BioRestorative Therapies, Inc. (NasdaqCM: BRTX)
Health Care · Biotechnology · US
$0.21
-0.98% today · -85.7% 1Y
BioRestorative Therapies, Inc. (NasdaqCM: BRTX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $5.49M and employs 14 people.
Over the last twelve months the share price has lost 85.7%, trading between 0.16 and 1.89.
Tweenvest scores BioRestorative Therapies, Inc. across four factors: quality 28/100, value 60/100. Its strongest factor is value.
BRTX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $5.49M
- Revenue (TTM)
- $357.87K
- P/E
- —
- EPS
- -0.98
- Dividend yield
- —
- Beta (5Y)
- 0.74
- 52-week high
- $1.89
- 52-week low
- $0.16
- Avg volume (3M)
- —
- Shares outstanding
- 25.48M
- Employees
- 14
- Next earnings
- —
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic disorders. Within their disc/spine program, known as brtxDisc, the company's leading cell therapy candidate is BRTX-100. This treatment involves culturing mesenchymal stem cells harvested from a patient's own bone marrow (autologous) to provide a non-surgical solution for painful lumbosacral disc conditions. BRTX-100 has successfully completed Phase 1 clinical trials. The company is also advancing its Metabolic Program, named ThermoStem, which is currently in the preclinical stage. This cell-based therapy targets obesity and other metabolic ailments by employing brown adipose-derived stem cells to generate brown adipose tissue. Beyond these core programs, BioRestorative Therapies also offers an investigational curved needle device designed for delivering cells and various therapeutic materials to the spine and discs. The company fosters strategic research and development partnerships, including agreements with Rohto Pharmaceutical Co., Ltd., Pfizer, Inc., and the University of Pennsylvania. Founded in 1997 and headquartered in Melville, New York, the company was initially known as Stem Cell Assurance, Inc., before rebranding to BioRestorative Therapies, Inc. in August 2011.
- ISIN
- US0906556065
- Listed since
- Dec 5, 2012
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €875.40 | +1.30% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $138.89 | -4.26% |
Figures last refreshed Aug 18, 2026.